Skip to Content Facebook Feature Image

HK Tech 300 Expo showcases hundreds of CityUHK incubated start-up innovations and achievements

Business

HK Tech 300 Expo showcases hundreds of CityUHK incubated start-up innovations and achievements
Business

Business

HK Tech 300 Expo showcases hundreds of CityUHK incubated start-up innovations and achievements

2025-05-23 19:16 Last Updated At:19:35

HONG KONG, May 23, 2025 /PRNewswire/ -- City University of Hong Kong (CityUHK) held the HK Tech 300 Expo, a large-scale innovation and entrepreneurship exhibition, from 23 to 24 May 2025 at the University campus. The two-day event brought together about 300 start-ups incubated by CityUHK with more than 60 roadshows, demonstrating how the University's world-class research achievements and innovative ideas translate into practical applications that foster positive social changes.  

Together with the Expo Opening Ceremony today (23 May 2025), CityUHK held the Launch Ceremony of the HK Tech 300 International Start-up Competition (HK Tech 300 International Competition), further expanding its innovation footprint onto the global stage.

Presiding over the ceremony were Professor Sun Dong, JP, Secretary for Innovation, Technology and Industry of the HKSAR Government, Mr Michael Ngai, Council Chairman of CityUHK, Mr Charles Chin Ying-on, Treasurer of CityUHK, and Professor Freddy Boey, President of CityUHK.

Also attending the ceremony were Mr Chaturont Chaiyakam, Consul-General of Thailand in the HKSAR, Mrs Le Duc Hanh, Consul-General of Vietnam in the HKSAR, and representatives from the governments and partner organisations of 12 mainland cities.

Professor Sun praised CityUHK's efforts in supporting young talent and nurturing start-ups. "CityUHK and HK Tech 300 play a crucial role in creating a vibrant ecosystem that fosters cross-disciplinary, cross-sector and cross-industry collaboration.  We must work together to support our young entrepreneurs, providing them with necessary resources, mentorship and opportunities to enhance their ideas into impactful solutions, further bolstering the development of Hong Kong as an international I&T hub."

In his welcome speech, Mr Ngai said the Expo marks a significant milestone in the University's journey to promote innovation and entrepreneurship. "CityUHK is dedicated to fostering a diverse environment for young talent, leveraging the robust support of the mainland, the University's base in Hong Kong and global connectivity to equip our next generation to become future leaders with a global vision," he said. 

"Innovation is the beacon of future development," said Professor Boey in his vote of thanks. "The remarkable achievements of HK Tech 300 and the start-ups are closely linked to the extensive support from, and collaboration among, the Government, industry, the University and investors. CityUHK will continue to provide a world-class platform, empowering the growth of our young talent and deep-tech start-ups."

Since its launch in 2021, HK Tech 300, CityUHK's flagship innovation and entrepreneurship programme, has incubated over 900 start-ups, more than 200 of which have received up to HK$1M each in angel funding. Beyond financial support and patent resources, HK Tech 300 offers extensive assistance, including business matching and co-investment opportunities, leveraging the expertise of over 250 mentors from diverse industries, alongside partnerships with more than 100 public and private institutions.

The HK Tech 300 Expo showcases nearly 300 start-ups incubated by CityUHK, offering a range of innovative solutions in the fields of Biotech & Health, ICT & AI, Advanced tech & ESG, and Fintech. The expo also features remarkable teams recognised under the Government's "Research, Academic and Industry Sectors One-plus Scheme (RAISe+)", as well as business proposals from the inaugural graduates of the MSc in Venture Creation programme at the CityUHK Academy of Innovation.  

CityUHK expanded the reach of HK Tech 300 to include the national region in 2022 and the Southeast Asian region in 2023. The introduction of the HK Tech 300 International Competition will foster further cross-border collaboration to address pressing global challenges.

The HK Tech 300 International Competition will be held in partnership with 11 universities and five local partners, including business chambers and incubators from nine countries and cities: Brunei, Hungary, Indonesia, Kazakhstan, Malaysia, Thailand, Turkey, Vietnam and Hong Kong SAR, numerous of universities' Vice-Chancellors and representatives attended the competition launch ceremony. The competition aims to attract aspiring talent and start-ups to Hong Kong and the mainland, leveraging the city's unique advantages and resources. It also empowers our local start-ups to reach the international stage and promote the University's technology transfer, fostering closer ties between the I&E ecosystem in Hong Kong and the rest of the world.

In addition to strategic partners, co-investors and supporting organisations from overseas and Mainland China, the event attracted legislative councillors, community leaders and school principals to witness the achievements of the start-ups. More than 60 innovation start-ups and research teams are participating in the Expo roadshows, fostering fruitful exchanges of innovation and business ideas. 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

HK Tech 300 Expo showcases hundreds of CityUHK incubated start-up innovations and achievements

HK Tech 300 Expo showcases hundreds of CityUHK incubated start-up innovations and achievements

T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors

Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer

Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors

FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.

"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."

Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.

 

 

To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.

Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.

"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."

About Alamar Biosciences, Inc. 
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com

 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team

Recommended Articles